Financial Data and Key Metrics Changes - The company recorded revenue of $3.4 million in Q1 2025, down from $3.8 million in Q1 2024, attributed to capital budget impacts from certain inpatient rehabilitation facilities related to the EksoNR enterprise health product [7] - Gross profit for Q1 was $1.8 million, representing a gross margin of approximately 54%, compared to a gross profit of $2 million and a gross margin of 52% for the same period in 2024 [8] - Operating expenses for Q1 2025 were $5.3 million, essentially unchanged from $5.2 million in Q1 2024 [9] - Net loss applicable to common stockholders for Q1 2025 was $2.9 million or $0.12 per share, compared to a net loss of $3.4 million or $0.20 per share in Q1 2024 [9] - Cash and restricted cash as of March 31, 2025, was $8.1 million, up from $6.5 million at the end of 2024 [10] Business Line Data and Key Metrics Changes - The enterprise health segment saw a reduction in revenue, while the Ekso Indigo Personal experienced good growth, indicating a shift in revenue contributions [11] - The company has developed a pipeline of over 35 Medicare beneficiaries qualified for the Ekso Indigo Personal in 2025, a 37% increase from the previous quarter [13] Market Data and Key Metrics Changes - The company noted softness in the legacy enterprise business due to capital budget impacts from customers reacting to macroeconomic uncertainties [11] - The regulatory change by CMS in Q2 2024 created significant opportunities for the Ekso Indigo Personal, removing barriers for Medicare enrollees with spinal cord injuries [11] Company Strategy and Development Direction - The company is focusing on building a scalable go-to-market strategy for the Ekso Indigo Personal, leveraging partnerships with Priya Healthcare and Bionic P and O to enhance market access [12][14] - The majority of revenue in 2025 is expected to still come from enterprise health, but significant contributions from personal health products are anticipated as the year progresses [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growing pipeline of Medicare beneficiaries and the potential for increased contributions from personal health products throughout 2025 [17] - There are concerns about the impact of economic uncertainties on capital budgets, particularly for inpatient rehabilitation facilities, which could affect future sales [27] Other Important Information - The company has engaged with National Seating and Mobility as an exclusive distributor for the Ekso Indigo Personal within the U.S. Complex Rehabilitation Technology industry [14] - The partnerships with distribution networks are expected to enhance the company's ability to process claims and improve operational efficiency [39][41] Q&A Session Summary Question: How should investors think about where the patients will fall this year in terms of the Indigo Personal? - Management expects that enterprise products will represent 75% to 80% of the business, with solid contributions from personal products growing quarter over quarter [20] Question: Any more color on how things are going with claims submissions? - Management believes they have a strong understanding of what constitutes a solid claim and that current submissions have a high probability of success [24] Question: What is the outlook on capital budgeting from IDNs? - Management noted that while there was softness in Q1, they expect solid contributions from IDNs in 2025 as many renewals are on track [26] Question: Is the current gross margin a new baseline? - Management believes that with continued operational improvements, gross margins can be maintained or improved as revenues expand [29]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37854 Ekso Bionics Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 99-0367049 ...

Exhibit 99.1 Ekso Bionics Announces First Quarter 2025 Financial Results SAN RAFAEL, Calif., May 5, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments "Over the past few weeks, we have significantly expanded access to Ekso Indego Personal via potentially transformative ...

Core Viewpoint - Ekso Bionics Holdings, Inc. reported its financial results for the first quarter of 2025, highlighting a decrease in revenue primarily due to lower sales of legacy devices, while also noting significant partnerships that may enhance future growth in the Personal Health products segment [1][4][11]. Financial Performance - The company recorded revenue of $3.4 million for the quarter ended March 31, 2025, down from $3.8 million in the same period in 2024, mainly due to lower sales of legacy EksoNR devices, although sales of Ekso Indego Personal devices increased [4]. - Gross profit for the first quarter was $1.8 million, with a gross margin of approximately 53.5%, compared to $2.0 million and a gross margin of 51.9% in the prior year, driven by cost savings in the supply chain [5]. - Sales and marketing expenses decreased to $1.7 million from $1.8 million year-over-year, attributed to lower headcount and travel expenses [6]. - Research and development expenses were $1.0 million, down from $1.1 million in the previous year, mainly due to reduced use of product development consultants [7]. - General and administrative expenses increased to $2.6 million from $2.3 million, primarily due to an impairment loss of an intangible asset and higher legal and audit costs [8]. - The net loss applicable to common stockholders was $2.9 million, or $0.12 per share, compared to a net loss of $3.4 million, or $0.20 per share, in the same quarter of 2024 [9]. Cash Flow and Position - The company used $2.0 million of net cash in operations for the first quarter of 2025, a decrease from $3.5 million in the same period in 2024 [9]. - As of March 31, 2025, the company had cash and restricted cash totaling $8.1 million, an increase from $6.5 million at the end of 2024 [9][16]. Strategic Partnerships - Ekso Bionics has formed partnerships with National Seating & Mobility (NSM) and Bionic Prosthetics & Orthotics Group (Bionic P&O), which are expected to enhance access to the Ekso Indego Personal device in the complex rehabilitation technology and orthotics and prosthetics markets, respectively [3][11].

Core Insights - Ekso Bionics Holdings, Inc. is set to release its financial and business results for Q1 2025 on May 5, 2025, after market close [1] - A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and recent business developments [1] Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in both medical and industrial applications [3] - The company focuses on improving health and quality of life through advanced robotics that restore and amplify human function [3] - Ekso Bionics is unique in offering technologies that assist individuals with paralysis to stand and walk, as well as enhancing capabilities in various job sites globally [3] - The company is headquartered in the San Francisco Bay Area and is publicly traded on the Nasdaq under the symbol "EKSO" [3]

Core Insights - Ekso Bionics Holdings, Inc. has appointed Bionic Prosthetics & Orthotics Group LLC as a non-exclusive distributor for its Ekso Indego® Personal device, enhancing its market reach in the orthotics and prosthetics industry [1][3] Company Overview - Ekso Bionics is a leader in exoskeleton technology, focusing on medical and industrial applications, with a mission to improve health and quality of life through advanced robotics [4] - The company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [4] Product Details - The Ekso Indego Personal is a lightweight, portable lower extremity powered exoskeleton designed for individuals with spinal cord injuries, enabling them to stand and walk independently [2] - It features a modular quick connect design for ease of use, allowing users to put on and take off the device without assistance [2] - The device has shown to help users achieve faster walking speeds, enhancing their independence in the community [2] Strategic Partnership - The collaboration with Bionic P&O is seen as a strategic move to leverage their expertise in the orthotics and prosthetics market, which is crucial for the successful marketing and distribution of the Ekso Indego Personal [3] - Bionic P&O, founded in 2007, operates across 12 states and is fully accredited, employing certified practitioners in various specialties [5] Market Impact - The partnership aims to empower individuals with spinal cord injuries to pursue their goals of walking again, potentially transforming the orthotics and prosthetics industry [3]

As filed with the Securities and Exchange Commission on August 28, 2024. Registration No. 333-281081 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S‑1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EKSO BIONICS HOLDINGS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Mark B. Baudler Austin D. March Wilson Sonsini Goodr ...

As filed with the Securities and Exchange Commission on July 29, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EKSO BIONICS HOLDINGS, INC. (Exact name of Registrant as specified in its charter) (Primary Standard Industrial Classification Code Number) Nevada 3841 99-0367049 (I.R.S. Employer Identification Number) 101 Glacier Point, SuiteA San Rafael, California 94901 (510) 984-1761 (Address, ...